Market Research Industry Reports

Aquestive Therapeutics - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Aquestive Therapeutics (Aquestive) formerly known as Monosol Rx, is a pharmaceutical company that discovers, develops and commercializes prescription drug products and a pipeline of prescription formulations. The company offers PharmFilm, a drug delivery platform that delivers existing prescription products directly to the bloodstream. Its products include zuplenz, suboxone, rizatriptan, diazepam, meloxicam, clobazam, colchicine, flu vaccine, and others. Aquestive also provides nutraceutical and various consumer products, packaging solutions, and drug products for the treatment of opioid dependence, nausea and vomiting. The company partners with other pharmaceutical companies for the development and commercialization of pharmaceutical products. It has manufacturing facility located in Portage, Indiana, the US. Aquestive is headquartered in Warren, New Jersey, the US.

Aquestive Therapeutics - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Aquestive Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aquestive Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aquestive Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aquestive Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aquestive Therapeutics, Medical Devices Deals, 2012 to YTD 2018 9
Aquestive Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aquestive Therapeutics, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Monosol Acquires Buccal Film Patent From Fuisz Pharma 11
Partnerships 12
Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 12
Midatech Enters Into Joint Venture With MonoSol Rx 14
Licensing Agreements 15
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 15
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz 16
Monosol Rx Enters Into Licensing Agreement With Vestiq Pharma For Zuplenz 17
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 18
Aquestive Therapeutics - Key Competitors 19
Aquestive Therapeutics - Key Employees 20
Aquestive Therapeutics - Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 21
Recent Developments 22
Corporate Communications 22
Apr 11, 2017: MonoSol Rx Appoints James S. Scibetta to Board of Directors 22
Jan 24, 2017: MonoSol Rx Appoints John T. Maxwell as Chief Financial Officer 23
Product News 24
01/06/2017: Monosol Rx Successfully Completes Dose Proportionality Study Of Diazepam Buccal Soluble Film To Treat Acute Repetitive Seizures 24
Product Approvals 25
Jan 31, 2018: Aquestive Therapeutics Receives U.S. FDA Orphan Drug Designation for Riluzole Oral Soluble Film to Treat ALS 25
Feb 07, 2017: MonoSol Rx Receives FDA Acceptance of New Drug Application for Tadalafil PharmFilm 26
Jan 04, 2017: MonoSol Rx Receives FDA Acceptance of Investigational New Drug Application for Riluzole Oral Soluble Film to Treat Amyotrophic Lateral Sclerosis 27
Clinical Trials 28
Jan 10, 2017: MonoSol Rx to Initiate Human Proof-of-Concept Study of Epinephrine Sublingual Soluble Film 28
Other Significant Developments 29
Nov 30, 2017: MonoSol Rx Changes Name to Aquestive Therapeutics and Expands CNS Product Portfolio 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List Of Tables

List of Tables
Aquestive Therapeutics, Pharmaceuticals & Healthcare, Key Facts 2
Aquestive Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aquestive Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aquestive Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aquestive Therapeutics, Deals By Therapy Area, 2012 to YTD 2018 8
Aquestive Therapeutics, Medical Devices Deals, 2012 to YTD 2018 9
Aquestive Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Monosol Acquires Buccal Film Patent From Fuisz Pharma 11
Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 12
Midatech Enters Into Joint Venture With MonoSol Rx 14
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 15
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz 16
Monosol Rx Enters Into Licensing Agreement With Vestiq Pharma For Zuplenz 17
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 18
Aquestive Therapeutics, Key Competitors 19
Aquestive Therapeutics, Key Employees 20
Aquestive Therapeutics, Other Locations 21
Aquestive Therapeutics, Joint Venture 21

List Of Figures

List of Figures
Express Scripts Holding Co, Performance Chart (2013 - 2017) 33
Express Scripts Holding Co, Ratio Charts 35
Express Scripts Holding Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Express Scripts Holding Co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 37

Aquestive Therapeutics - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aquestive Therapeutics (Aquestive) formerly known as Monosol Rx, is a pharmaceutical company that discovers, develops and commercializes prescription drug products and a pipeline of prescription formulations. The company offers PharmFilm,

USD 250View Report

CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report

CRISPR Therapeutics - Strategy, SWOT and Corporate Finance ReportCRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the

USD 175View Report

CRISPR Therapeutics - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

CRISPR Therapeutics - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines CRISPR Therapeutics Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :30
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube